Shares of BioScrip Inc. (NASDAQ:BIOS) fell 2.9% during mid-day trading on Friday . The company traded as low as $2.65 and last traded at $2.67, with a volume of 188,836 shares traded. The stock had previously closed at $2.75.

Separately, Zacks Investment Research raised shares of BioScrip from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research report on Monday, July 11th.

The firm’s market cap is $301.78 million. The firm’s 50-day moving average is $2.68 and its 200 day moving average is $2.46.

BioScrip (NASDAQ:BIOS) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by $0.05. The business earned $232.50 million during the quarter, compared to analysts’ expectations of $229.58 million. BioScrip’s revenue was down 11.4% compared to the same quarter last year. On average, equities research analysts expect that BioScrip Inc. will post ($0.27) EPS for the current year.

In other news, Director David W. Golding acquired 12,500 shares of the company’s stock in a transaction on Friday, June 17th. The stock was purchased at an average cost of $2.48 per share, with a total value of $31,000.00. Following the acquisition, the director now owns 42,500 shares of the company’s stock, valued at approximately $105,400. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Coliseum Capital Management, L bought 4,200,000 shares of the firm’s stock in a transaction dated Wednesday, June 22nd. The shares were bought at an average price of $2.00 per share, with a total value of $8,400,000.00. The disclosure for this purchase can be found here.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.